



APSS, Trento, Italy, Begins Patient Treatments

The 1st proton therapy center with isocentric gantries in Italy treated its 1st patient

Trento, Italy, November 19, 2014 - The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announced today that The Trento Proton Therapy Center has begun proton therapy treatments on October 22, 2014.

The Trento facility is the first proton therapy center with isocentric gantries in Italy. The site is already equipped with Pencil Beam Scanning (PBS) technology. It furthermore boasts advanced features such as multiple spot ID and high precision positioning and will be the first IBA complex with CT-on-rails imagery installed. Initially, it will mainly be used for treating sarcoma and tumors in the brain, at the base of skull and in the cervical cephalic region, in pediatric as well as adult cases. Once in full operation, it is expected to treat about 700 patients a year.

The program of the Italian Ministry of Health provides 5 supra-regional proton therapy units in Italy and a national coordination unit (CNAO of Pavia), i.e., a center for every 8 million inhabitants. There are 150,000 cancer patients who are treated with radiation therapy each year, and 10% of these can benefit from proton therapy treatment. The Trento Proton Therapy Center, linked to the Santa Chiara Hospital, was commissioned by and operates under the Trento Health Authority (APSS).

Dr. Maurizio Amichetti, MD, Clinical Director of the Proton Therapy Center, commented: "We are proud and thrilled to announce that the proton therapy center of the Trento Hospital has become operational. We believe this is a major leap forward in the care of our patients and that Intensity Modulated Proton Therapy will become ever more important as new features will broaden its scope and enhance its efficacy. Starting patient treatment crowns the first stage of an intense collaboration between APSS and the IBA team to bring proton therapy to Trento and we are confident that it marks the beginning of an ever-increasing success in our fight against cancer."

"We were all looking forward to this moment," says **Dr. Marco Scwarz, Head of Medical Physics of the Proton Therapy Center, commented.** "For several years now APSS and the IBA crew have jointly been working towards the goal to not only construct the first proton therapy center with isocentric gantries in Italy, but make sure it's equipped with state-of-the-art technology. Now we can continue our journey and concentrate on adding this cutting-edge therapy to our cancer patients' treatment options."

Olivier Legrain, IBA CEO added: The first patient treatment in a new proton therapy center is a triumph every single time. It proves that APSS made the right choice by putting its trust in IBA to bring proton therapy to Trento and have Italian cancer patients benefit from the undeniable advantages of this cancer care modality. Together we will make it our mission to further refine proton therapy practices in order to obtain ever better treatment outcomes."

- END -



About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. www.iba-protontherapy.com

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 16 proton therapy centers in operation and 10 additional centers under development. Over 25,000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About the Azienda Provinciale per I Servizi Sanitari (APSS)

The Trento Health Authority (APSS) was set up in 1995 through the union of 11 local health units. The Trust ensures the delivery of all 'essential levels of care' set out by the Italian government plus additional services established by the Provincial government. It is one of the largest health authorities in Italy with over 7.900 employees, 830 general practitioners, pediatricians and other specialists operating within its organization and 523.000 people registered. It handles direct management of 7 hospitals and 4 health districts with 31 outpatient treatment units, 3 structural departments (laboratory, radiodiagnosticians, anesthesia and intensive care) and has agreements with 7 hospitals, 17 outpatient treatment units and 55 nursing homes to provide health services.



For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal
+44 (0) 207 920 2333
IBA@consilium-comms.com